Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/enzalutamide (Enz) sensitive and resistant metastatic castrate-resistant prostate cancer (mCRPC).

Eric J. Small,Lawrence Fong,David I. Quinn,Charles G. Drake,Dwayne Campogan,Tuyen Vu,Nadeem A. Sheikh,Nancy N. Chang,Daniel Peter Petrylak

Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/enzalutamide (Enz) sensitive and resistant metastatic castrate-resistant prostate cancer (mCRPC).

2016

Eric J. Small
Lawrence Fong
David I. Quinn
Charles G. Drake
Dwayne Campogan
Tuyen Vu
Nadeem A. Sheikh
Nancy N. Chang
Daniel Peter Petrylak

5077Background: Immune responses to Sip-T in mCRPC patients (pts) correlate with survival (NEJM 2010;363:411). Adding Abi or Enz to Sip-T does not blunt Sip-T immune responses (CCR 2015;21:3862; JC...

Keywords:

Sipuleucel-T
Abiraterone
Oncology
Immunogenicity
Pathology
Castrate-resistant prostate cancer
Enzalutamide
Internal medicine
Medicine
Immune system

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations